Skip to content
Peptide research

HGH Fragment 176-191

Also known as HGH Frag · Frag 176-191
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic 16-amino-acid piece of growth hormone marketed for targeted fat loss without raising blood sugar or IGF-1. Nearly all supporting human data comes from a related peptide (AOD-9604), not this exact fragment, so real human evidence is thin and rests mostly on animal and mechanism studies. No published human safety trials exist for the unmodified peptide, and unregulated products sold online vary widely in quality. Not FDA-approved, and prohibited by WADA.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

HGH Fragment 176-191 is a synthetic peptide made of 16 amino acids, corresponding to the C-terminal end of human growth hormone. It represents the minimal region of the full 191-amino-acid growth hormone molecule responsible for its fat-metabolizing properties. First characterized in the late 1970s at Monash University in Australia, related fragments have shown fat-metabolism effects in laboratory studies, but those results do not establish the unmodified fragment's effectiveness or freedom from growth, IGF-1, or blood-sugar effects in humans. It is the parent compound of AOD-9604, a modified version that has been more extensively studied in humans.

How it works in the body

The C-terminal portion of human growth hormone (amino acids 176-191). Related AOD-9604 increased beta-3 receptor expression but did not act directly through that receptor. Its laboratory findings do not establish the unmodified fragment's mechanism or human glucose safety.

Research overview

Research on this fragment spans nearly five decades, but a critical distinction must be understood: the unmodified HGH Fragment 176-191 has never been tested in published human clinical trials. Most clinical claims attributed to it actually come from studies on AOD-9604, a slightly modified version. Related hGH 177–191, AOD-9401, and AOD-9604 showed metabolic effects in mice. In beta-3 receptor knockout mice, AOD-9604 did not produce the chronic weight and lipolysis responses but retained acute metabolic responses. While AOD-9604 has been tested in six human trials with over 900 participants, consumers should be aware that products sold as 'HGH Fragment 176-191' are not the same compound that was tested in those clinical studies.

Who researches HGH Fragment 176-191?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

  • People researching experimental oncology peptides

    Studied for effects on cancer cell targeting or tumor biology in preclinical research.

Important considerations for

  • Those with Active cancer

    Moderate

    Fragment of GH with primarily lipolytic activity. Lower cancer risk than full GH but caution still warranted.

  • Those with Diabetes/hypoglycemia risk

    Moderate

    Can affect glucose metabolism. Monitor blood sugar when combined with antidiabetic agents.

  • Those who are pregnant or breastfeeding

    Absolute

    No reproductive safety data for this GH fragment.

Safety & interactions

Do not use if

  • Active cancer

    Moderate

    Fragment of GH with primarily lipolytic activity. Lower cancer risk than full GH but caution still warranted.

  • Diabetes/hypoglycemia risk

    Moderate

    Can affect glucose metabolism. Monitor blood sugar when combined with antidiabetic agents.

General cautions

  • Pregnancy

    Absolute

    No reproductive safety data for this GH fragment.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(12)

Rated by level of concern

  • No published human clinical trial safety data exists for the unmodified HGH Fragment 176-191 (all human data is for AOD-9604 derivative)

    High

    PubMed: no human trials of unmodified hGH 176-191; ClinicalTrials.gov API query 'AOD9604' returns totalCount 0 (note Australian trials would register on ANZCTR, not CT.gov); Stier et al. J Endocrinol Metab 2013 [sponsor-affiliated]

  • High-dose administration caused hyperglycemia and reduced insulin sensitivity in rats (Ng & Bornstein 1978)

    Moderate

    PMID 645904; PMID 429095; PMID 6810951

  • FDA has cited immunogenicity (immune reaction) concerns for the closely related AOD-9604 peptide

    Moderate

    FDA, 'Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks' (503A Category 2 list) and FDA's interim review of AOD-9604

  • FDA has cited concerns about peptide impurity profiles in compounded formulations of related peptides

    Moderate

    FDA 503A bulk drug substances Category 2 list and accompanying peptide reviews

  • Limited long-term safety data — longest AOD-9604 trial was 24 weeks; no data for unmodified fragment

    Moderate

    Stier et al. J Endocrinol Metab 2013 [sponsor-affiliated]

  • Quality control variability in unregulated products sold online

    High

    PMID 24976118 (Drug Test Anal 2014, Belgian seizure case report); FDA 503A Category 2 peptide reviews

  • Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)

    Low

    General peptide pharmaceutics; no compound-specific stability study published for hGH 176-191

  • Injection site reactions including redness, swelling, and irritation (reported anecdotally)

    Low

    Stier et al. J Endocrinol Metab 2013 [sponsor-affiliated]; user-community reports (non-primary)

  • Transient headache reported anecdotally in user communities

    Low

    Stier et al. J Endocrinol Metab 2013 [sponsor-affiliated]; user-community reports (non-primary)

  • Prohibited by WADA — positive test could result in sanctions for competitive athletes

    High

    WADA Prohibited List, class S2; PMID 25208511 (AOD9604-specific); PMID 26213263 (general sports drug testing review — contextual)

  • No data on safety during pregnancy or lactation

    Moderate

    Absence of published data — no reproductive toxicology in PubMed for hGH 176-191 or AOD-9604

  • Extrapolating AOD-9604 safety data to the unmodified fragment involves scientific uncertainty — the single amino acid difference could alter immunogenicity, stability, or pharmacokinetics

    Moderate

    PMID 15134286 (AOD-9604 drug profile, Curr Opin Investig Drugs 2004); PMID 25208511 (AOD9604 in vitro metabolism)

Interaction summary(8)

Rated by direction with this peptide

  • Beta-3 adrenergic receptor agonists (e.g., mirabegron)

    SynergisticTheoretical

    Rodent work shows hGH and AOD9604 restore adipose beta-3-AR expression and lipolytic sensitivity, so co-administration with a beta-3 agonist is a plausible amplifier of lipolysis. In the same study the chronic weight/fat effects persisted in beta-3-AR knockout mice, so beta-3 signalling is not the sole pathway and the synergy is speculative. Never tested in any species.

    PMID 11713213 (Endocrinology 2001, beta-3-AR knock-out mice)

  • Non-selective beta-blockers (e.g., propranolol, carvedilol)

    CautionTheoretical

    In the cited study, chronic AOD9604 effects were retained in beta-3-AR knockout mice. Acute lipolysis is beta-adrenergically modulated, so beta-blockade could blunt the intended effect, but the chronic component appears at least partly beta-3-independent. Either way the concern is reduced efficacy, not toxicity.

    PMID 11713213

  • Insulin and insulin secretagogues (sulfonylureas, meglitinides)

    CautionTheoretical

    The hyperglycemic/diabetogenic signal for C-terminal hGH fragments is high-dose rodent data only, and no human interaction study of any kind exists. Chronic low-dose AOD9604 showed no clamp-measured insulin-sensitivity impairment in rats. Reasonable to monitor glycemic control in insulin-treated users, but no human evidence of a real interaction.

    PMID 645904; PMID 429095; PMID 11146367

  • Recombinant human growth hormone and GH secretagogues (CJC-1295, ipamorelin, tesamorelin)

    CautionTheoretical

    Using intact hGH or GH secretagogues with the fragment is redundant and potentially counterproductive: intact hGH carries the insulin-desensitizing and IGF-1-raising effects the fragment was specifically engineered to avoid, and no combination safety or efficacy data exists in any species.

    PMID 11146367 (hGH impaired insulin sensitivity where AOD9604 did not); PMID 11713213

  • Systemic corticosteroids (e.g., prednisone, dexamethasone)

    CautionTheoretical

    Corticosteroids promote lipogenesis, visceral fat accumulation, and insulin resistance, directly opposing the fragment's intended metabolic direction. The expected consequence is an attenuated effect rather than added harm — this is an efficacy caution, not a toxicity one. No interaction study published.

    Mechanistic — established corticosteroid metabolic pharmacology; no interaction study published

  • Sympathomimetic stimulants and thermogenic agents (caffeine, ephedrine, clenbuterol, yohimbine)

    CautionTheoretical

    The fragment has no direct catecholaminergic or sympathomimetic activity. What is plausible is convergent stimulation of adipocyte lipolysis and raised free fatty acids when used with agents that do drive beta-adrenergic signaling; the cardiovascular effects (tachycardia, tremor) belong to the stimulants themselves. No published safety evaluation of this combination exists.

    Mechanistic — convergence on adipose lipolysis; PMID 11713213

  • GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)

    NeutralTheoretical

    No pharmacokinetic or pharmacodynamic interaction is known or expected — the mechanisms (central appetite/incretin signalling versus peripheral adipocyte lipolysis) are independent — but no combination data exists to confirm additive benefit or safety.

    Mechanistic; no published combination study

  • Anti-doping testing programs (WADA-governed competition)

    CautionHigh

    Not a pharmacologic interaction but a clinically actionable one: AOD9604 and related hGH fragments fall under WADA class S2, prohibited at all times, and a validated LC-MS/MS method with characterized in vitro metabolites has been published for AOD9604. The consequence is a sanction, whatever the pharmacology.

    WADA Prohibited List class S2; PMID 25208511; PMID 26213263 (general MS sports-testing review — contextual)

Known risks(12)

  • No published human clinical trial safety data exists for the unmodified HGH Fragment 176-191 (all human data is for AOD-9604 derivative)

  • High-dose administration caused hyperglycemia and reduced insulin sensitivity in rats (Ng & Bornstein 1978)

  • FDA has cited immunogenicity (immune reaction) concerns for the closely related AOD-9604 peptide

  • FDA has cited concerns about peptide impurity profiles in compounded formulations of related peptides

  • Limited long-term safety data — longest AOD-9604 trial was 24 weeks; no data for unmodified fragment

  • Quality control variability in unregulated products sold online

  • Potential for degradation and loss of efficacy if improperly stored (peptide stability concerns)

  • Injection site reactions including redness, swelling, and irritation (reported anecdotally)

  • Transient headache reported anecdotally in user communities

  • Prohibited by WADA — positive test could result in sanctions for competitive athletes

  • No data on safety during pregnancy or lactation

  • Extrapolating AOD-9604 safety data to the unmodified fragment involves scientific uncertainty — the single amino acid difference could alter immunogenicity, stability, or pharmacokinetics

Drug interactions(6)

  • Human Growth Hormone (HGH/Somatropin)

    Theoretical — avoid co-administration

    Theoretical additive or competitive interaction — both act on overlapping lipolytic pathways via the C-terminal domain. The fragment may compete with or complement the metabolic effects of full-length HGH. Co-administration has not been studied.

  • Beta-3 Adrenergic Agonists (e.g., mirabegron)

    Theoretical — use caution

    HGH Fragment 176-191 modulates beta-3-AR expression. Co-administration with pharmacological beta-3 agonists could theoretically potentiate adrenergic signaling in adipose tissue.

  • Insulin and Oral Hypoglycemics

    Low-moderate risk — monitor glucose, especially at higher doses

    The 1978 Ng & Bornstein study showed hyperglycemic action of C-terminal HGH fragments at high doses, though the AOD-9604 derivative showed no glucose effects in clinical trials. Patients on diabetes medications should monitor blood glucose.

  • AOD-9604

    Redundant — no rationale for co-administration

    Structurally near-identical peptide (differs by one amino acid). Co-administration would be redundant and could increase total peptide load without added benefit. Not studied together.

  • Other GH-releasing peptides (CJC-1295, Ipamorelin, Sermorelin, GHRP-6)

    Unknown — no formal studies

    These peptides stimulate endogenous GH release, which would include the full C-terminal domain. No evidence-based safety data exist for using them with the isolated fragment.

  • Corticosteroids

    Pharmacological antagonism — may reduce efficacy

    Chronic corticosteroid use promotes adipogenesis and visceral fat accumulation, potentially counteracting the lipolytic effects of HGH Fragment 176-191.

Research & benefits

Evidence base

Total Studies
15
Human Studies
0

Researched for(9)

Rated by confidence in the evidence

  • Stimulates lipolysis (fat breakdown) in adipose tissue

    Medium

    The cited rodent, human-tissue, and clinical findings concern related fragments, including AOD-9401 and AOD-9604, rather than a human trial of unmodified hGH 176–191.

    PMID 10950816; PMID 11146367; PMID 11673763; PMID 11713213

  • Inhibits lipogenesis (new fat formation)

    Low

    Shown in animal and ex vivo human tissue studies, but from one research group only.

    PMID 8358331 (Antilipogenic action of synthetic C-terminal sequence 177-191 of hGH, Biochem Mol Biol Int 1993); PMID 10950816

  • Does not elevate IGF-1 levels

    Speculative

    Shown for the related compound AOD9604 in human trials, not directly tested for this fragment.

    Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab 2013;3(1-2):7-15 (doi:10.4021/jem139w, non-PubMed-indexed, sponsor-affiliated); Wilding J. AOD-9604 Metabolic. Curr Opin Investig Drugs 2004;5(4):436-40 (PMID 15134286, secondary drug-profile review). Both sources describe AOD9604, a modified analog (Tyr-hGH 177-191) that underwent human trials and later failed Phase 2b efficacy testing. Unmodified HGH Fragment 176-191 has no direct human IGF-1 trial data of its own; the claim for this peptide rests on structural/mechanistic reasoning (isolated lipolytic domain, no GH-receptor activation) rather than a primary trial in this specific molecule.

  • Does not impair glucose homeostasis or insulin sensitivity at therapeutic doses

    Speculative

    Human glucose safety is unestablished for unmodified hGH 176–191; early rat work reported increased glucose and insulin. Favorable findings concern related AOD-9604.

    PMID 11146367 (Metabolic studies of a synthetic lipolytic domain (AOD9604) of hGH, Horm Res 2000); PMID 645904 (contrasting high-dose finding); Stier et al. J Endocrinol Metab 2013 [sponsor-affiliated]

  • Increases fat oxidation and energy expenditure

    Low

    Increased fat oxidation and energy expenditure shown in mice, not yet confirmed by human calorimetry.

    PMID 10950816; PMID 11673763; PMID 11713213 (beta-3-AR knock-out mouse study, Endocrinology 2001)

  • Selectively targets fat metabolism without growth-promoting effects

    Low

    No growth-related effects are well supported, but selective fat targeting lacks confirmed human data.

    PMID 11146367; PMID 11713213; Stier et al. J Endocrinol Metab 2013 [sponsor-affiliated]

  • May support cartilage repair (via AOD-9604 derivative data)

    Speculative

    Based on one rabbit knee study; no human data or established mechanism yet.

    PMID 26275694 (Ann Clin Lab Sci 2015, rabbit OA model)

  • Potential anticancer drug delivery enhancement

    Speculative

    Based on a single 2022 cell-culture study; no animal or human data yet.

    PMID 35783198 (Drug Des Devel Ther 2022)

  • Active via oral administration (demonstrated in animal models)

    Low

    Oral effects shown in two rodent models, but never confirmed pharmacokinetically in humans.

    PMID 10950816 (Effects of oral administration of a synthetic fragment of hGH on lipid metabolism, Am J Physiol Endocrinol Metab 2000); PMID 11146367

Benefits(9)

  • Stimulates lipolysis (fat breakdown) in adipose tissue

  • Related hGH 177–191 inhibited lipogenesis in obese mice; this is indirect evidence for unmodified hGH 176–191.

  • Does not elevate IGF-1 levels

  • Related AOD-9604 showed no adverse glucose or insulin effects in the cited studies; this has not established a therapeutic safety profile for unmodified hGH 176–191.

  • Increases fat oxidation and energy expenditure

  • Selectively targets fat metabolism without growth-promoting effects

  • May support cartilage repair (via AOD-9604 derivative data)

  • Potential anticancer drug delivery enhancement

  • Active via oral administration (demonstrated in animal models)

Key studies(6)

  1. Ng FM, Bornstein J

    American Journal of Physiology

    1978

    First characterization of synthetic C-terminal HGH fragments. Four peptides (hGH 172-191, 176-191, 177-191, 178-191) produced short-lived rise in blood glucose and sustained rise in plasma insulin in rats. Minimum informational sequence identified, and biological activity requires proper 3D conformation.

  2. Natera SH, Jiang WJ, Ng FM

    Biochemistry and Molecular Biology International

    1994

    Chronic treatment with hGH 177-191 reduced cumulative body weight gain and decreased adipose tissue mass in obese ob/ob mice. Lipogenesis was significantly inhibited. Authors concluded the fragment is 'the functional domain of hGH for the antilipogenic actions of the intact hormone.'

  3. Heffernan MA, Jiang WJ, Thorburn AW, Ng FM

    American Journal of Physiology - Endocrinology and Metabolism

    2000

    Oral AOD-9401 (synthetic HGH fragment) significantly reduced body weight gain from day 16 onward. Increased lipolytic activity and decreased lipogenic activity in isolated adipose tissue from both obese rodents and humans. Demonstrated oral bioavailability.

  4. Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM

    International Journal of Obesity and Related Metabolic Disorders

    2001

    Both HGH and AOD-9604 reduced body weight gain and increased in vivo fat oxidation in obese mice. Elevated plasma glycerol confirmed enhanced fat breakdown. Critical finding: AOD-9604 does not interact with the classical HGH receptor, suggesting a novel metabolic pathway.

  5. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM

    Endocrinology

    2001

    AOD-9604 and HGH increase beta-3 adrenergic receptor RNA expression in obese mice to lean levels. Knockout mice lacked the chronic weight and lipolysis response, but AOD-9604 still acutely increased energy expenditure and fat oxidation. The authors concluded that its lipolytic actions were not mediated directly through beta-3 adrenergic receptors.

  6. Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA

    Drug Design, Development and Therapy

    2022

    HGH Fragment 176-191 co-loaded with doxorubicin in chitosan nanoparticles enhanced anticancer toxicity against MCF-7 cells (IC50 1.5 vs 1.85 mcg/mL). Peptide shows high affinity to Ki-67, MiB protein, and estrogen receptor. Novel non-metabolic application.

Regulation & availability

Why researchers look at it

Designed to isolate growth hormone's fat-burning effects without the growth-promoting or blood-sugar-disrupting side effects, with Monash University animal studies consistently showing reduced body fat in obese mice. A critical distinction is often missed: the human data (six trials, 900+ participants) all used AOD-9604, a slightly modified derivative, and its Phase IIb trial (n=536) ultimately failed its primary endpoint. No published human trial has ever tested this unmodified fragment — its evidence base remains entirely preclinical.

FDA status
HGH Fragment 176-191 is not FDA-approved and is not eligible for compounding in the US. No FDA-approved therapeutic product containing unmodified hGH 176–191 was identified. It is a separate peptide from AOD-9604. AOD-9604's food-use GRAS claim was privately self-determined, not granted by FDA, and does not establish injectable safety or drug approval. FDA evaluated AOD-9604 for obesity at the December 4, 2024 PCAC meeting, where the committee recommended against inclusion on the 503A bulks list. That review does not itself determine the unmodified fragment's status.
WADA status
Prohibited in competition and out-of-competition. Explicitly listed by WADA under S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. The 2026 WADA Prohibited List (effective January 1, 2026) specifically names both 'hGH 176-191' and 'AOD-9604' as examples of prohibited growth hormone fragments. Athletes subject to anti-doping testing must not use HGH Fragment 176-191 under any circumstances.
Prescribability
HGH Fragment 176-191 is not FDA-approved and is not eligible for compounding in the US. AOD-9604 is a separate substance; its food-use GRAS claim was a private self-determination, not FDA review or approval. It is not a controlled substance but is prohibited in competitive sports by WADA.
Availability
HGH Fragment 176-191 is not approved as a pharmaceutical drug by any regulatory agency, and no FDA-approved pharmaceutical product containing unmodified hGH 176–191 was identified. It is not available through standard pharmacies or prescription channels. Availability from a clinic does not establish approval or lawful compounding. No qualifying bulk-compounding basis was established for this fragment. AOD-9604 is a different peptide; its food-use GRAS claim was privately self-determined rather than granted by FDA. The fragment is prohibited at all times under WADA's 2026 List.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(10)

  1. 1978
    Ng & Bornstein (Monash University, Australia) first characterize synthetic C-terminal HGH fragments including 176-191, demonstrating hyperglycemic and metabolic activity in rats (PMID: 645904).
  2. 1994
    Natera, Jiang & Ng publish chronic treatment study: hGH 177-191 reduces body weight gain and adipose tissue mass in obese mice, establishing the fragment as the 'functional domain' for antilipogenic action (PMID: 7987248).
  3. 1998
    Metabolic Pharmaceuticals Ltd. (Melbourne, Australia) develops AOD-9604, a modified version of HGH Fragment 176-191 with N-terminal tyrosine substitution, for clinical development as an anti-obesity drug.
  4. 2000
    Heffernan et al. demonstrate oral bioavailability and lipolytic effects of synthetic HGH fragment (AOD-9401) in rodent and human adipose tissue (PMID: 10950816).
  5. 2001
    Two landmark Heffernan et al. studies published: (1) fat oxidation/weight loss comparison of HGH vs AOD-9604 in obese mice (PMID: 11673763), (2) beta-3-AR mechanism confirmation using knockout mice (PMID: 11713213).
  6. 2002
    Six human clinical trials conducted on AOD-9604 (not the unmodified fragment), including Phase IIa and the pivotal Phase IIb with 536 subjects.
  7. 2007
    Phase IIb trial fails to meet primary efficacy endpoint. Metabolic Pharmaceuticals terminates AOD-9604 drug development program.
  8. 2022
    Habibullah et al. publish novel application: HGH Fragment 176-191 enhances doxorubicin-loaded chitosan nanoparticle toxicity against breast cancer cells (PMID: 35783198).
  9. 2024
    FDA proposes NOT to include AOD-9604 on the 503A Bulks List for pharmaceutical compounding. Implications for the unmodified fragment are uncertain but likely restrictive.
  10. 2026
    WADA 2026 Prohibited List (effective Jan 1, 2026) explicitly names both 'hGH 176-191' and 'AOD-9604' as prohibited growth hormone fragments under S2. Regulatory dispute over compounding continues.

Sources & FAQs

Research sources(9)

Frequently asked questions(7)

What is the difference between HGH Fragment 176-191 and AOD-9604?

HGH Fragment 176-191 is the native sequence (amino acids 176-191) of human growth hormone, beginning with phenylalanine (Phe). AOD-9604 is a modified version where the N-terminal phenylalanine is replaced with tyrosine (Tyr), adding one hydroxyl group to improve peptide stability. AOD-9604 should be thought of as an optimized, research-developed analog. The critical practical difference is that all six human clinical trials (900+ participants) were conducted on AOD-9604, not the unmodified fragment. When safety or efficacy claims cite clinical data for 'HGH Frag 176-191,' they are almost always referencing AOD-9604 studies.

Has HGH Fragment 176-191 been tested in humans?

No. As of 2026, HGH Fragment 176-191 (the unmodified native sequence) has not been studied in published human clinical trials. All human clinical data comes from AOD-9604 (the modified derivative). Animal studies dating back to 1978 have consistently demonstrated lipolytic and anti-lipogenic effects in obese rodent models, and one study showed effects on human adipose tissue in vitro.

How does HGH Fragment 176-191 work for fat loss?

In laboratory studies, related fragments stimulated lipolysis (fat breakdown) and inhibited lipogenesis (new fat formation) in adipose tissue. The receptor findings concern AOD-9604: beta-3 receptor expression increased, but knockout mice retained acute metabolic responses. Separate cell assays found no hGH receptor binding or proliferation; this does not establish the unmodified fragment's human safety.

Is HGH Fragment 176-191 safe?

Direct human safety data for the unmodified fragment does not exist. Safety extrapolations are based on AOD-9604 trials, which showed adverse events comparable to placebo across all dose groups with no serious adverse events attributed to the peptide. The fragments share 15 of 16 amino acids. However, the FDA has raised concerns about immunogenicity, peptide impurity profiles, and limited long-term data for AOD-9604, which would apply equally or more to the unmodified fragment.

Can HGH Fragment 176-191 cause cancer or promote tumor growth?

Unlike full-length HGH, the fragment does not elevate IGF-1 levels or activate growth-promoting signaling pathways, which theoretically reduces cancer risk. Interestingly, a 2022 study (Habibullah et al.) found that the fragment actually enhanced the toxicity of doxorubicin against breast cancer cells when co-loaded in nanoparticles. However, long-term cancer safety data from human studies is absent.

How is HGH Fragment 176-191 typically used?

In non-clinical settings, it is typically administered via subcutaneous injection. This use is derived from community practice rather than clinical trial data for the unmodified fragment.

Is HGH Fragment 176-191 legal?

It is not a controlled substance in most jurisdictions. It is NOT legal for use in competitive sports — WADA explicitly lists 'hGH 176-191' alongside AOD-9604 under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as prohibited both in and out of competition. Its status for pharmaceutical compounding is uncertain.